PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer

Shinichi Sakamoto*, Kodai Sato, Takahiro Kimura, Yoshiyuki Matsui, Yusuke Shiraishi, Kohei Hashimoto, Hideaki Miyake, Shintaro Narita, Jun Miki, Ryuji Matsumoto, Takuma Kato, Toshihiro Saito, Ryotaro Tomida, Masaki Shiota, Akira Joraku, Naoki Terada, Shigetaka Suekane, Tomoyuki Kaneko, Shuichi Tatarano, Yuko YoshioTakayuki Yoshino, Naotaka Nishiyama, Eiryo Kawakami, Tomohiko Ichikawa, Hiroshi Kitamura

*この論文の責任著者

研究成果: ジャーナルへの寄稿学術論文査読

1 被引用数 (Scopus)

抄録

A multicenter study of nonmetastatic castration-resistant prostate cancer (nmCRPC) was conducted to identify the optimal cut-off value of prostate-specific antigen (PSA) doubling time (PSADT) that correlated with the prognosis in Japanese nmCRPC. Of the 515 patients diagnosed and treated for nmCRPC at 25 participating Japanese Urological Oncology Group centers, 450 patients with complete clinical information were included. The prognostic values of clinical factors were evaluated with respect to prostate specific antigen progression-free (PFS), cancer-specific survival (CSS), and overall survival (OS). The optimal cutoff value of PSADT was identified using survival tree analysis by Python. The Median PSA and PSADT at diagnosis of nmCRPC were 3.3 ng/ml, and 5.2 months, respectively. Patients treated with novel hormonal therapy (NHT) showed significantly longer PFS (HR: hazard ratio 0.38, p < 0.0001) and PFS2 (HR 0.45, p < 0.0001) than those treated with vintage nonsteroidal antiandrogen agent (Vintage). The survival tree identified 4.65 months as the most prognostic PSADT cutoff point. Among the clinical and pathological factors PSADT of < 4.65 months remained an independent prognostic factor for OS (HR 2.96, p = 0.0003) and CSS (HR 3.66, p < 0.0001). Current data represented optimal cut-off of PSADT 4.65 months for a Japanese nmCRPC.

本文言語英語
論文番号15307
ジャーナルScientific Reports
14
1
DOI
出版ステータス出版済み - 2024/12

ASJC Scopus 主題領域

  • 一般

フィンガープリント

「PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル